Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome

Trial ID or NCT#

NCT02502162,,

Status

recruiting iconRECRUITING

Purpose

The investigators are testing treatment with low-dose naltrexone (LDN) for symptom relief of complex regional pain syndrome (CRPS). Study participants will be randomly assigned to receive either LDN or placebo for a period of several weeks. During this period participants will be asked to attend either in-person or virtual study visits and complete questionnaires.

Official Title

Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome

Eligibility Criteria

Ages Eligible for Study: 18 Years to 70 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Upper and/or lower extremity CRPS - On stable treatment for 1 month - CRPS for at least 1 year - Meet the Budapest criteria for CRPS at time of the study.
Exclusion Criteria:
  1. - Any known allergy to naltrexone or naloxone - Use of prescription opioid analgesics or illegal opioid use - Current or planned pregnancy.

Investigator(s)

Sean Mackey, M.D., Ph.D.
Sean Mackey, M.D., Ph.D.
Pain management specialist, Pain management specialist, Anesthesiologist
Redlich Professor, Professor of Anesthesiology, Perioperative, and Pain Medicine and, by courtesy, of Neurology

Contact us to find out if this trial is right for you.

Contact

Birute Gedrimaite
650-497-0485